,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['breast', 'enhertu', '$azn', '$dsnky']
enhertu nearly halves risk of disease progression in her2-low breast cancer study $azn $dsnky #asco22 
The latest global #pharma news, insights, analysis, and views providing you with an information edge.  FirstWord Pharma. Where people who know first, go first.